Gain Therapeutics Presents GT-02287 Update
Analysis based on 7 articles · First reported Apr 24, 2026 · Last updated Apr 24, 2026
The announcement of Gain Therapeutics' oral presentation on GT-02287, a promising drug candidate for Parkinson s disease, is likely to generate positive market sentiment for Gain Therapeutics. Successful clinical trial results and continued development could lead to increased investor confidence and potential stock price appreciation for Gain Therapeutics.
Gain Therapeutics, a clinical-stage biotechnology company, announced an oral presentation at the 3rd International GBA1 Meeting 2026, where its Chief Medical Officer, Jonas Hannestad, will provide an update on the development of GT-02287 for Parkinson s disease. GT-02287 is Gain Therapeutics' lead drug candidate, an allosteric enzyme modulator designed to restore the function of glucocerebrosidase (GCase) in Parkinson s disease patients, with or without a GBA1 mutation. Preclinical and Phase 1 study results have shown favorable safety, tolerability, and target engagement, with initial Phase 1b results demonstrating central nervous system target engagement and improvements in MDS-UPDRS scores. The program has received funding from The Michael J. Fox Foundation, The Silverstein Foundation for Parkinson s with GBA, and the Eurostar joint program, co-funded by the European Union Horizon 2020 research and Switzerland — Innosuisse - Swiss Innovation Agency. Gain Therapeutics management will also attend the 7th World Parkinson's Congress.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard